Joost Peerbooms

90 Chapter 6 Table 2 DASH and VAS scores for the Corticosteroid Group and the PRP Group at the Various Time Points (Intention-to-Treat Analyses) α DASH VAS Time Intervention Mean ± SD P Value Mean ± SD P Value Baseline Corticosteroid 43.3 ± 16.1 .002 66.2 ± 14.0 .340 PRP 54.3 ± 19.5 69.0 ± 15.9 4 weeks Corticosteroid 31.2 ±6 20.8 .005 44.3 ± 26.3 .023 PRP 43.1 ± 21.6 55.7 ± 24.1 8 weeks Corticosteroid 28.3 ± 22.2 .060 43.4 ±28.9 .411 PRP 37.2 ± 24.7 47.7 ± 25.0 12 weeks Corticosteroid 32.3 ± 21.7 .813 45.5 ± 27.1 .319 PRP 21.3 ± 22.0 40.2 ± 27.5 26 weeks Corticosteroid 37.6 ± 23.1 .037 55.8 ± 24.1 <.0001 PRP 27.8 ± 24.7 32.9 ± 30.8 52 weeks Corticosteroid 36.8 ± 24.0 <.0001 48.8 ± 27.0 <.0001 PRP 20.0 ± 23.5 25.9 ± 30.6 104 weeks Corticosteroid 36.5 ± 23.8 <.0001 42.4 ± 26.8 <.0001 PRP 17.6 ± 24.0 21.3 ± 28.1 α DASH, Disabilities of the Arm, Shoulder and Hand outcome measure; VAS, visual analogue scale; PRP, platelet-rich plasma; SD, standard deviation Successful Treatment (VAS Score) In total, 60 of 100 patients were successfully treated, which was defined as a reduction of 25% on the VAS pain score without a reintervention after 2 years. Table 3 shows that the PRP group was more often treated successfully (n = 39) than the corticosteroid group (n = 21; P < .0001). However, compared with baseline VAS pain scores, a number of patients (n = 11) had deteriorated in VAS pain scores at 2-year follow-up. Of these 11 patients, the majority received a corticosteroid injection (n = 9), while 2 patients received a PRP injection ( P = .017). Eventually, 1 patient had received a reinjection with corticosteroids, 1 patient crossed over to the PRP group, and 2 patients received surgery.